Skip to Main Content

Gilead Sciences and Arcus Biosciences said Monday that an experimental cancer immunotherapy directed against a target called TIGIT reduced the risk of tumor progression or death by 45% in a mid-stage clinical trial involving patients with lung cancer.

The new data for the drug called domvanalimab were not tested for statistical significance and will need to be confirmed in a larger, Phase 3 study, but the preliminary results will likely be seen as a boost to the ongoing partnership between Gilead and the smaller biotech Arcus, established in 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment